JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1985; 5:101-107
© 1985 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franciosa, J.
Right arrow Articles by Jordan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franciosa, J.
Right arrow Articles by Jordan, R.

Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure

JA Franciosa, MM Wilen, and RA Jordan

Angiotensin-converting enzyme inhibitors are effective vasodilators in the treatment of congestive heart failure. Enalapril, a new angiotensin-converting enzyme inhibitor, or placebo, in addition to digoxin and diuretic drugs, were given to 17 patients with chronic congestive heart failure who were followed up for 12 weeks. In random double-blind fashion, nine patients received enalapril and eight received placebo. Cardiac dimensions and function improved slightly but insignificantly in both groups. Treadmill exercise duration increased from a mean value (+/- standard deviation) of 9.1 +/- 3.2 to 12.0 +/- 3.5 minutes during enalapril administration (p less than 0.025) and was unchanged during placebo administration (10.1 +/- 3.7 versus 11.1 +/- 5.2 minutes). Maximal oxygen consumption also increased during enalapril therapy (15.8 +/- 3.4 to 18.4 +/- 4.4 ml/min per kg, p less than 0.05) and remained unchanged during placebo treatment (16.0 +/- 6.4 versus 17.0 +/- 4.6 ml/min per kg). Clinical functional class (Yale scale) improved 3.1 +/- 1.9 points (p less than 0.01) during enalapril treatment but not during placebo treatment (0.8 +/- 3.5 points, no significant difference). No significant side effects were observed. Thus, enalapril appears to be a clinically effective and useful new angiotensin-converting enzyme inhibitor for the management of chronic congestive heart failure.


This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
C. T. Pu, M. T. Johnson, D. E. Forman, J. M. Hausdorff, R. Roubenoff, M. Foldvari, R. A. Fielding, and M. A. F. Singh
Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure
J Appl Physiol, June 1, 2001; 90(6): 2341 - 2350.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
W. T. Abraham
Pharmacologic Management of Chronic Heart Failure: A Review
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
H. Kamishirado, T. Inoue, T. Fujito, M. Kase, M. Shimizu, Y. Sakai, K. Takayanagi, S. Morooka, S. Natsui, and H. Kamishirado
Effect of Enalapril Maleate on Cerebral Blood Flow in Patients with Chronic Heart Failure
Angiology, August 1, 1997; 48(8): 707 - 713.
[Abstract] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1985 by the American College of Cardiology Foundation.